Study identifier:D5200C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I Single-blind, Randomised, Placebo-controlled, Single-centre Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AZD4721 Solution After Single Ascending Doses, and to Compare the Oral Bioavailability of Single Doses of Solution and Suspension in Healthy Subjects
Safety,plasma AUC and Cmax, plasma AUC 0-t, t1/2λz, and tmax
Phase 1
Yes
AZD4721 Solution, AZD4721 Placebo, AZD4721 Suspension
All
44
Interventional
18 Years - 50 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verified 01 Jun 2015 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Part A Active AZD4721 Solution | Drug: AZD4721 Solution 1-9 mg/mL liquid solution |
Placebo Comparator: Part A Placebo Placebo for AZD4721 | Drug: AZD4721 Placebo Liquid solution |
Experimental: Part B solution AZD4721 Solution | Drug: AZD4721 Solution 1-9 mg/mL liquid solution |
Active Comparator: Part B Suspension AZD4721 Suspension | Drug: AZD4721 Suspension 9 mg/g liquid suspension |